Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro

Dermatology

Volumn 206, Issue 3, 2003, Pages 225-232

  Alpsoy, E ^a,b   Kodelja, V ^a   Goerdt, S ^a   Orfanos, C E ^a   Zouboulis, Christos C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MKU University School of Medicine   (Turkey)

Author keywords

AMAC 1; Beh et's disease; CD64; Interleukin 8; Macrophages; Serum

Indexed keywords

ANTIGEN; BETA CHEMOKINE; CD 163 ANTIGEN; CD16 ANTIGEN; CD64 ANTIGEN; CHEMOKINE; DEXAMETHASONE; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 4; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BEHCET DISEASE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETAL CALF SERUM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SERUM;

ADULT; BEHCET SYNDROME; CHEMOKINES, CC; FEMALE; HUMANS; INTERLEUKIN-8; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; RECEPTORS, IGG;

EID: 0037250226     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068888     Document Type: Article

References (43)

1. Sakane T, Takeno M, Suzuki N, Inaba G: Behçet's disease. N Engl J Med 1999;341:1284-1291.
2. Sakane T, Suzuki N, Nagafuchi H: Etiopathology of Behçet disease: Immunological aspects. Yonsei Med J 1997;38:350-358.
3. Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, Söhnchen R, Weber H, Gollnick HPM, Hölzle E, Fritz K, Licht T, Orfanos CE: Epidemiological features of Ada-mantiades-Behćet's disease in Germany and in Europe. Yonsei Med J 1997;38:411-422.
4. Adler YD, Mansmann U, Zouboulis CC: Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease. Dermatology 2001;203:322-324.
5. Alpsoy E, Yilmaz E, Coskun M, Savas A, Yegin O: HLA antigens and linkage disequilibrium patterns in Turkish Behçet's patients. J Dermatol 1998;25:158-162.
6. Goerdt S, Orfanos CE: Other functions, other genes: Alternative activation of antigen-presenting cells. Immunity 1999;10:137-142.
7. Stein M, Keshav S, Harris N, Gordon S: Interleukin-4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-292.
8. Goerdt S, Bhardwaj R, Sorg C: Inducible expression of MS-1 high molecular weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol 1993;142:1409-1422.
9. Zwadlo G, Voegeli R, Schulze-Osthoff K, Sorg C: A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 1987;55:295-304.
10. Zwadlo G, Bröcker EB, von Bassewitz DB, Feige U, Sorg C: A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol 1985;134:1487-1492.
11. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, Goerdt S: Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998;160:1411-1418.
12. International Study Group for Behc̈et's disease: Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-1080.
13. Kodelja V, Goerdt S: Dissection of macrophage differentiation pathways in cutaneous macrophage disorders and in vitro. Exp Dermatol 1994;3:257-268.
14. Goerdt S, Walsh LJ, Murphy GF, Pober JS: Identification of a novel high molecular weight protein antigen preferentially expressed by sinusoidal endothelial cells in normal human tissues. J Cell Biol 1991;113:1425-1437.
15. Walsh LJ, Goerdt S, Pober JS, Sueki H, Murphy GF: MS-1 sinusoidal endothelial antigen is expressed by factor XIIIa+, HLA-DR+ dermal perivascular dendritic cells. Lab Invest 1991;65:732-741.
16. Zwadlo-Klarwasser G, Bent S, Haubeck HD, Sorg C, Schmutzler W: Glucocorticoid-induced appearance of the macrophage subtype RM3/1 in peripheral blood in man. Int Arch Allergy Appl Immunol 1980;91:175-180.
17. Åström A, Tavakkol A, Pettersson U, Cromie M, Elder JT, Voorhees JJ: Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP). Retinoic acid-induced expression of CRABP-II but not CRABP-I in adult human skin in vivo and in skin fibroblasts in vitro. J Biol Chem 1991;266:17662-17666.
18. Becker S, Daniel EG: Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: Effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990;129:351-362.
19. de Velde AA, Huijbens RJ, de Vries JE, Figdor CG: IL-4 decreases Fc gamma R membrane expression and Fc gamma R-mediated cytotoxic activity of human monocytes. J Immunol 1990;144:3046-3051.
20. Goerdt S, Kolde G, Bonsmann G, Hamann K, Czarnetzki B, Andreesen R, Luger T, Sorg C: Immunohistochemical comparison of cutaneous histiocytoses and related skin disorders: Diagnostic and histogenetic relevance of MS-1 high molecular weight protein expression. J Pathol 1993:170:421-427.
21. Wenzel I, Roth J, Sorg C: Identification of a novel surface molecule, RM3/1, that contributes to the adhesion of glucocorticoid-induced human monocytes to endothelial cells. Eur J Immunol 1996;26:2758-2763.
22. Goerdt S, Kodelja V, Schmuth M, Orfanos CE, Sorg C: The mononuclear phagocyte-dendritic cell dichotomy: Myths, facts, and a revised concept. Clin Exp Immunol 1996;105:1-9.
23. Topoll H, Zwadlo G, Lange DE, Sorg C: Phenotypic dynamics of macrophage subpopulations during human experimental gingivitis. J Periodontal Res 1989;24:106-112.
24. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, Koch AE: Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia: Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994;37:221-231.
25. Djemadji-Oudjiel N, Goerdt S, Kodelja V, Schmuth M, Orfanos CE: Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM3/1+++, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res 1996;288:757-764.
26. Ravetch JV: Fc receptors. Curr Opin Immunol 1997;9:121-125.
27. Baggiolini M, Dewald B, Moser B: Human chemokines: An update. Annu Rev Immunol 1997;15:675-705.
28. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, Kaklamanis P, Orfanos CE: Adamantiades-Behçet's disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000;292:279-284.
29. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC: Adamantiades-Behçet's disease: Serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000;201:37-39.
30. Kienbaum S, Zouboulis CC, Waibel M, Orfanos CE: Chemotactic neutrophilic vasculitis: A new histopathological pattern of vasculitis found in mucocutaneous lesions of patients with Adamantiades-Behçet's disease; in Wechsler B, Godeau P (eds): Behçet's Disease. International Congress Series 1037. Amsterdam, Excerpta Medica, 1993, pp 337-341.
31. Rizzi B, Bruno S, Dammacco R: Behçet's disease: An immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997;27:225-232.
32. Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J: Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patient's with Behçet's disease. Clin Exp Immunol 1990;79:28-34.
33. Lew W, Lee SH, Bang D, Lee S, Kim JC, Chung TH: Serum tumor necrosis factor, interleukin-1-beta and interleukin-6 levels in Behçet's disease. Ann Dermatol 1993;5:69-73.
34. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C: Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-1549.
35. Itoh R, Takenaka T, Okitsu-Negishi S, Matsu-shima K, Mizogouchi M: Interleukin 8 in Behçet's disease. J Dermatol 1994;21:397-404.
36. Sayinalp N, Özcebe OI, Özdemir O, Haznedaroglu IC, Dündar S, Kirazli S: Cytokines in Behçet's disease. J Rheumatol 1996;23:321-322.
37. Alpsoy E, Cayirli C, Er H, Yilmaz E: The levels of plasma interleukin-2 and soluble interleukin-2r in Behçet's disease, as a marker of disease activity. J Dermatol 1998;25:513-516.
38. Zouboulis CC: Morbus Adamantiades-Behçet: Klinische und experimentelle Untersuchungen - Erhebungen an 53 Patienten aus dem Berliner Raum; Habilitationsschrift, Fachbereich Humanmedizin der Freien Universität Berlin, 1995.
39. Lee KH, Bang D, Choi ES, Chun WH, Lee ES, Lee S: Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behçet's disease. Arch Dermatol Res 1999;291:374-381.
40. Boyvat A, Sisman-Solak C, Gurler A: Long-term effects of interferon alpha 2a treatment in Behçet's disease. Dermatology 2000;201:40-43.
41. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-1016.
42. Alpsoy E, Durusoy Ç, Yilmaz E, Özgürel Y, Ermis O, Yazar S, Basaran E: Interferon alpha-2a in the treatment of Behçet's disease: A randomized, placebo-controlled and double blind study. Arch Dermatol 2002;138:467-471.
43. Katsantonis J, Seltmann H, Wróbel A, Adler YD, Hornemann S, Orfanos CE, Zouboulis CC: Xenobiotic regulation of endothelial intra-cellular and secreted interleukin-8 induced by serum of patients with Adamantiades-Behçets disease; in Bang D, Lee E-S, Lee S (eds): Behçet's Disease. Proceedings of the 9th International Conference on Behçet's Disease and the 8th International Conference on Behcȩt's Disease. Seoul, Library of Congress Cataloging, 2001, pp 236-239.